The WAIT-AF trial is recruiting 200 adults with atrial fibrillation and overweight or obesity to test whether semaglutide 2.4 mg given before a first catheter ablation improves arrhythmia-free survival at 12 months. It is the first randomized trial of the GLP-1 receptor agonist in this procedural…
Semaglutide now faces its first randomized test as a pre-ablation treatment for atrial fibrillation . The WAIT-AF study, registered under the identifier NCT07275697 and led by Emma Svennberg, the lead sponsor, is currently recruiting 200 adults with atrial fibrillation and overweight or obesity. The question is whether 2.4 mg semaglutide, started before a first catheter ablation , improves arrhythmia-free survival 12 months after the procedure. The study record was last updated on 2026-08-10, when the trial was listed as enrolling.
The trial targets a documented gap. Atrial fibrillation is the most common heart rhythm disorder and is associated with symptoms, reduced quality of life, heart failure, and stroke, and with a high risk of recurrence after catheter ablation. Overweight or obesity is one of the strongest predictors of recurrence in patients scheduled for a first ablation. Weight loss and risk-factor management are known to improve ablation outcomes, but lifestyle changes are often difficult to achieve and sustain in routine care.
What is new is the combination of drug, timing, and endpoint. Prior evidence addressed semaglutide's weight-loss and metabolic and cardiovascular effects, and weight loss as a general way to improve ablation outcomes. Whether semaglutide before ablation improves long-term rhythm outcomes has never been tested in a randomized clinical trial. WAIT-AF is a Phase 4 trial, a post-marketing test in a population for which the drug is already approved.
Eligible participants are adults scheduled for their first catheter ablation for atrial fibrillation with a BMI of at least 30 kg/m², or a BMI of at least 27 kg/m² plus at least one additional cardiovascular risk factor such as hypertension, diabetes, or dyslipidemia. Those criteria place the trial inside the population for which semaglutide Wegovy is approved in the European Union for weight management.
The 200 participants are randomized 1:1 to standard medical treatment or semaglutide plus lifestyle advice. Semaglutide is administered according to the approved EU label with gradual dose escalation. Every participant receives an implantable loop recorder before ablation, so heart rhythm is monitored continuously through follow-up rather than sampled at clinic visits.
The primary endpoint is arrhythmia-free survival 12 months after ablation. Recurrence is defined as atrial fibrillation, atrial flutter, or atrial tachycardia lasting at least 30 seconds on continuous loop recorder monitoring, with the standard 3-month blanking period after ablation excluded from the definition. Secondary endpoints are:
The trial is open-label: participants and treating clinicians know the assigned arm. That is the main limitation, and it is real in a weight-management study, because knowledge of assignment can shape diet, exercise, and other care on both sides. The design does address one major source of bias: endpoint assessment is blinded, so recurrence is adjudicated from loop recorder data without knowledge of treatment assignment.
Continuous monitoring is a methodological strength. AF recurrence is often asymptomatic, and intermittent electrocardiographic follow-up misses a large share of episodes. An implantable loop recorder captures every episode reaching the 30-second threshold, and the 3-month blanking period removes the transient post-ablation inflammatory window, when arrhythmias are common and not predictive of long-term failure. These choices match the standards used to define ablation success and give the trial a rigorous, prespecified outcome.
The design cannot separate a direct drug effect from drug-mediated behavior change if the semaglutide arm does better, although that distinction may matter less if the combined strategy works. It also cannot settle the central question yet: no efficacy or safety results are available because the trial is still recruiting. The record does not state the overall trial duration, so durability beyond the 12-month primary analysis is not addressed by this registration.
Semaglutide is a GLP-1 receptor agonist approved in the European Union as Wegovy for weight management. WAIT-AF uses that existing approval: a Phase 4 trial administers an approved drug to an approved population, in this case adults with a BMI of at least 30 kg/m², or at least 27 kg/m² with one additional cardiovascular risk factor. What is novel is not the peptide but its position in care. Giving semaglutide before a first ablation, and measuring arrhythmia-free survival rather than weight, tests a clinical strategy that the product label does not describe.
Phase 4 trials have a defined regulatory logic. They generate evidence on how a drug performs in real-world or targeted populations after approval, and they can inform practice and future regulatory submissions. This trial does not by itself constitute an application to approve semaglutide for an atrial fibrillation indication. A positive result would establish proof of concept that peptide-mediated weight management before ablation changes rhythm outcomes. Whether that would lead to a label change would depend on confirmatory evidence and a new regulatory submission.
The EU frame also governs how the drug is given. Dose escalation, monitoring, and the safety and tolerability assessments follow the approved European label. WAIT-AF is therefore a test of an approved peptide in a new clinical position, not a test of a new molecular entity.
Atrial fibrillation is maintained by an atrial substrate: structural changes such as chamber dilatation and fibrosis, plus electrical changes that shorten refractory periods and favor re-entry. Obesity pushes the atrium in that direction through multiple routes, including accumulation of fat within and around the atrial wall, increased atrial pressure and wall stress, systemic inflammation, and a higher prevalence of hypertension and diabetes. Weight loss reduces that load, and that is the established basis for the claim that weight loss improves ablation outcomes.
Semaglutide acts upstream of the heart. As a GLP-1 receptor agonist, it reinforces glucose-dependent insulin secretion and acts on central GLP-1 receptors to reduce appetite and food intake. The result, demonstrated in prior studies, is substantial and sustained weight loss along with improvement in metabolic and cardiovascular risk factors. The WAIT-AF hypothesis is that weight loss achieved reliably before ablation modifies the substrate that drives recurrence, so the procedure is performed on a less abnormal atrium with less stretch and a lower inflammatory burden.
Whether any rhythm benefit is purely a weight effect or partly a direct action of the peptide is not knowable from this design. GLP-1 receptor signaling extends beyond metabolism, and cardiovascular outcome research on semaglutide is active, but WAIT-AF is built to answer a practical question: does giving the peptide before ablation improve outcomes, whatever the pathway?
WAIT-AF enters a large and expanding semaglutide research program. The Peptide Atlas file on semaglutide lists 668 registered clinical trials, with 10 currently recruiting. Of the trials with phase designations on file, four are Phase 2, four are Phase 4, and one is Phase 3. The Phase 4 activity in particular shows a drug being tested across indications beyond obesity. Named trials on file include:
The metabolic surgery trial for AF elimination is the closest conceptual neighbor to WAIT-AF. It tests whether weight loss achieved surgically improves AF outcomes in patients with obesity; WAIT-AF tests whether weight loss achieved with a peptide does. Together they bracket the question of how much of the AF benefit depends on the weight loss itself rather than the method.
The indexed literature on file at Peptide Atlas includes 197 PubMed papers. Recent examples cover long-term safety and renal outcomes of semaglutide in non-diabetic obesity with chronic kidney disease or hypertension Clin Ter , weight-lowering drugs and natural female fertility Clin Obes , semaglutide and effort-based decision-making in major depressive disorder JAMA Psychiatry , the STRIDE trial in peripheral artery disease and diabetes European Heart Journal , and a scoping review of retinal vascular event risk Ophthalmologica . The pattern is consistent: semaglutide research is moving beyond metabolic risk-factor modification into organ-specific outcomes, psychiatric applications, perioperative settings, and now procedural electrophysiology.
For clinicians, the trial is not yet actionable. It is recruiting, and no efficacy or safety results exist. An electrophysiologist weighing whether to start semaglutide before ablation in a patient with a BMI above 30 cannot yet cite outcome data in support. The value at this stage is that WAIT-AF will generate those data, and its design sets the evidentiary bar for the field: randomized assignment, continuous rhythm monitoring in all participants, a prespecified recurrence definition, and blinded adjudication.
The recurrence definition also has clinical meaning. A threshold of 30 seconds and a 3-month blanking period are the conventions used to define ablation success, so a result from WAIT-AF will be comparable to the wider ablation literature. The secondary endpoints on symptoms, quality of life, blood pressure, metabolic risk factors, repeat ablation, and cardiovascular hospitalizations will give a fuller picture, but as secondary analyses in 200 participants they will not support definitive conclusions on their own.
The supply chain relevance runs in two directions. Inside the trial, semaglutide is the approved EU product administered per label with gradual dose escalation, so trial supply follows the regulated commercial chain. For the wider research community, semaglutide is among the most studied peptides in medicine, and quality control of research-grade material is a separate question from pharmaceutical quality. Peptide Atlas holds eight third-party laboratory purity tests for semaglutide, with the highest observed purity at 99.979%. That figure is a reference point, and it underscores why laboratories handling the peptide for research should verify purity rather than assume it.
Three questions dominate. First, will semaglutide improve long-term rhythm outcomes rather than only weight and metabolic measures? Weight loss is expected in an open-label semaglutide arm; the arrhythmia result is not assured. Second, will the strategy improve overall cardiovascular health in AF patients with overweight or obesity? The secondary endpoints address blood pressure, metabolic risk, symptoms, quality of life, and cardiovascular hospitalizations, but the study is sized for its…
Peptides referenced: Semaglutide, GLP-1.
Related reading: Semaglutide Biomarker Gains Clash With Missed Alzheimer's Endpoints, UK first in Europe to approve Eli Lilly oral GLP-1 orforglipron, Microbiota safety should shape antimicrobial peptide development, Why Weight Returns After GLP-1 Agonist Therapy Is Stopped.